Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 38

Results For "NFI"

1393 News Found

Cupid’s B2B export order book stands at Rs. 100 Cr+
News | September 04, 2025

Cupid’s B2B export order book stands at Rs. 100 Cr+

These orders are from international government tenders in South Africa, Tanzania, and Kenya, as well as from international agencies WHO/UNFPA, NGOs like MSI and PSI


Syntegon reports H1 2025 EBITDA higher by 41% to €127 million
News | September 04, 2025

Syntegon reports H1 2025 EBITDA higher by 41% to €127 million

Free cash flow also reached €63 million, representing an 11 percent increase compared to the high benchmark set in 2024


Metal-free catalysis is transforming future of sustainable pharmaceutical innovation
Opinion | September 03, 2025

Metal-free catalysis is transforming future of sustainable pharmaceutical innovation

It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals


Novartis Leqvio demonstrates strong LDL-C goal achievement with reduced muscle pain
News | September 03, 2025

Novartis Leqvio demonstrates strong LDL-C goal achievement with reduced muscle pain

The trial is the largest to date evaluating Leqvio and the first to focus on patient-centered outcomes


Novo Nordisk’s Wegovy cuts risk of heart attack, stroke or death by 57% compared to tirzepatide
News | August 31, 2025

Novo Nordisk’s Wegovy cuts risk of heart attack, stroke or death by 57% compared to tirzepatide

The study showed a significant 29% reduction in the risk for heart attack, stroke and death from any cause in the Wegovy users


FDA approves Novavax's Nuvaxovid 2025-2026 formula for prevention of COVID-19
Drug Approval | August 31, 2025

FDA approves Novavax's Nuvaxovid 2025-2026 formula for prevention of COVID-19

Nuvaxovid is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season


Sai Life Sciences completes Phase II of production block 11 at Bidar
News | August 29, 2025

Sai Life Sciences completes Phase II of production block 11 at Bidar

With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL


Lighthouse receives $49.2 million NIA grant to advance phase 2 study of Alzheimer’s disease
News | August 28, 2025

Lighthouse receives $49.2 million NIA grant to advance phase 2 study of Alzheimer’s disease

LHP588 is an oral, brain-penetrant lysine-gingipain (Kgp) inhibitor designed to block the key virulence factor of P. gingivalis


argenx reports positive phase 3 ADAPT SERON results of VYVGART in AChR-Ab seronegative gMG
News | August 28, 2025

argenx reports positive phase 3 ADAPT SERON results of VYVGART in AChR-Ab seronegative gMG

VYVGART was well tolerated, with a safety profile consistent with prior studies in AChR-Ab seropositive gMG and other indications


SMS Pharmaceuticals receives EIR from USFDA for Central Laboratory Analytical Services
News | August 27, 2025

SMS Pharmaceuticals receives EIR from USFDA for Central Laboratory Analytical Services

The inspection, conducted from June 23 to June 25, 2025, concluded with zero Form 483 observations